Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Measles – new active ingredient may have a protective effect against local outbreaks?

17.04.2014

A newly developed inhibitory substance against the measles virus may protect individuals already infected from the disease and prevent the spreading of the virus. The inhibitory substance which can be administered in tablet form reduces the viral burden in animals infected with a virus which is closely related to the measles virus. Besides, it also protects the animals from a fatal course of the disease. In its online edition of Wednesday, 16th April (20:00 MEZ) Science Translational Medicine reports on research results from scientists at the Paul-Ehrlich-Institut and Georgia State University

Despite world-wide efforts to eradicate the disease, measles outbreaks still occur time and again among the German population due to incomplete vaccination rates. In 2013 alone, 1775 measles cases in Germany were reported to the Robert-Koch-Institute. Against this background, an inhibitory substance would be helpful which protects the patient after an infection with the virus and reduces the risk of further spreading of the virus.


Cells infected with drug-resistant (green fluorescence) and wild type (red fluorescence) recombinant canine distemper virus. Infected cells were treated with ERDRP-0519, or received solvent only

Foto: Georgia State University

Professor R. Plemper of the Institute for Biomedical Sciences, Georgia State University, Atlanta, USA, and colleagues have developed a low-molecular inhibitory substance against the measles virus, which is available for oral administration and could be administered in tablet form. The active substance, called ERDRP-0159, inhibits RNA-dependent RNA polymerase, which is indispensable for the replication of the virus.

Up to now, the development of a suitable inhibitory substance against virus has barely been possible because a suitable animal model for efficacy testing was not available. Dr Veronika von Messling, head of the Veterinary Medicine Division of the Paul-Ehrlich-Institut, and colleagues have succeeded in establishing an animal model in the ferret for this purpose. This project forms part of the institute’s involvement in the German Centre for Infection Research (DZIF).

The research group used a very close relative of the measles virus, the canine distemper virus (CDV) for their experiments. Like the measles virus, this virus belongs to the family of morbilliviruses. An infection with this virus will lead to fatal outcome in ferrets. However, if the animals were treated with the inhibitory substance for 14 days as from the third day after the infection, all ferrets survived the virus infection. Besides, the treatment, which was very well tolerated by the animals, conferred the development of immune protection against the measles virus. A new infection with the virus did not cause disease.

The most important obstacle to be overcome in the development of medicines against viruses is that the virus frequently develops resistance. Experiments with some virus variants showed that the infectious disease induced by them was attenuated or the course of the infection was slowed down. Dr Messing explains the results: “Our experiments allow us to forecast that such resistance development would not spread among the population – especially based on the fact that the measles outbreaks are as a rule locally restricted because the major part of the population has been vaccinated”.

The results obtained so far give rise to optimism. However, there are still some important questions to be answered. Thus, it must still be established whether treatment with the inhibitory substance against the measles will also confer immunity against the virus in humans after treatment, or whether subsequent vaccination would be necessary to assure long-term protection against a measles infection.

Original publication: Krumm SA, Yan D, Hovingh E, Evers TJ, Enkirch T, Reddy GP, Sun A, Saindane MT, Arrendale RF, Painter G, Liotta DC, Natchus MG, von Messling V, Plemper RK (2014). Orally Available Small-Molecule Polymerase Inhibitor Cures a Lethal Morbillivirus Infection.

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines in Langen near Frankfurt/Main, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and veterinary vaccines. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects. Other duties of the institute include official batch control, scientific advice and inspections.

In-house experimental research in the field of biomedicines and life science form an indispensable basis for the varied and many tasks performed at the institute. The PEI, with its roughly 800 staff, also has advisory functions at a national level (federal government, federal states (Länder)), and at an international level (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Weitere Informationen:

http://www.dzif.de German Centre for Infection Research (DZIF)
http://www.pei.de/EN/information/journalists-press/press-releases/press-releases... Paul-Ehrlich-Institut, Press releases

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

Further reports about: Arzneimittel DZIF Health Impfstoffe Medicine Paul-Ehrlich-Institut animals resistance vaccination

More articles from Life Sciences:

nachricht Researchers uncover protein-based “cancer signature”
05.12.2016 | Universität Basel

nachricht The Nagoya Protocol Creates Disadvantages for Many Countries when Applied to Microorganisms
05.12.2016 | Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>